Sudeep Pharma Limited (NSE: SUDEEPPHRM, BSE: 544619) is a Vadodara, Gujarat-based company in the Excipients and Mineral Actives industry. With a market capitalisation of ₹13,641 Cr, it ranks #495 by market cap among the 6,197 Indian listed companies on FinBizNet. At ₹1,195.60 (as of 16 Nov 2026), the share price is 13.2% below its 52-week high of ₹1,378.00 and 128.1% above its 52-week low of ₹524.05.
| Current Price | ₹1,195.60 |
|---|---|
| Market Cap | ₹13,641 Cr |
| NSE Symbol | SUDEEPPHRM |
| BSE Code | 544619 |
| Sector | Materials > Chemicals > Speciality Chemicals |
| Sub-Industry | Specialty Chemicals > Excipients and Mineral Actives |
| P/E Ratio | 77.9 |
| Return on Equity | 19.41% |
| Return on Assets | 13.68% |
| 52-Week Range | ₹524.05 – ₹1,378.00 |
| 3-Month Price Change | +8.9% |
| Beta (1Y) | 0.35 |
| Dividend Yield | 0.12% |
| Headquarters | Vadodara, Gujarat |
| Website | www.sudeeppharma.com |
| Revenue | ₹197 Cr |
|---|---|
| Net Profit | ₹52 Cr |
| Net Margin | 26.3% |
| EPS (Basic) | ₹4.59 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Sudeep Pharma Limited reported revenue of ₹197 Cr in Q2 FY27, up 20.9% from ₹163 Cr in Q2 FY26 and up 24.3% from ₹158 Cr in Q1 FY27. It posted a net profit of ₹52 Cr for the quarter, against a net profit of ₹47 Cr in Q2 FY26 (up 10.8%). Across the 5 quarters from Q2 FY26 to Q2 FY27, quarterly revenue ranged from ₹158 Cr (Q1 FY27) to ₹197 Cr (Q2 FY27). The company was profitable in each of these 5 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹197 Cr | ₹52 Cr | 26.3% |
| Q1 FY27 | ₹158 Cr | ₹41 Cr | 25.6% |
| Q4 FY26 | ₹182 Cr | ₹49 Cr | 26.6% |
| Q3 FY26 | ₹172 Cr | ₹48 Cr | 27.7% |
| Q2 FY26 | ₹163 Cr | ₹47 Cr | 28.8% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 76.15% of Sudeep Pharma Limited's shares as of Sept 2026, unchanged from Nov 2025. Delivery averaged 45.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in United States, Europe, United Kingdom, and Latin America. The company provides mineral salts, such as calcium, zinc, iron, potassium, magnesium, sodium, and copper to a range of health-focused applications; and calcium carbonate, which is used as an active pharmaceutical ingredient for various therapeutic applications. It also offers micronutrient premixes, encapsulated ingredients, liposomal and spray-dried formats, granulated minerals, and triturated blends to meet the needs across functional foods, dietary supplements, infant and clinical nutrition, fast-moving consumer goods, and convenience food formulations. In addition, the company is involved in manufacturing, developing, buying, selling, importing, exporting, trading, agency, testing, distributing, consigning, stocking, registering, packing, marketing, refining, and processing of pharmaceu
1. Pharmaceutical, Food and Nutrition-This segment offers pharmaceutical, food, and nutrition products. 2. Specialty Ingredients-This segment offers speciality ingredient. 3. Unallocated-NA 4. Specialty Chemicals-This segment offers specialty chemicals.
1. Pharmaceutical, Food and Nutrition-56.5% 2. Specialty Ingredients-43.5%
Sudeep Pharma Limited is trading at ₹1,195.60, with a market capitalisation of ₹13,641 Cr.
Sudeep Pharma Limited operates in the Materials > Chemicals > Speciality Chemicals space (Specialty Chemicals > Excipients and Mineral Actives).
Sudeep Pharma Limited has a P/E of 77.9 and a return on equity of 19.41%.
Sudeep Pharma Limited is listed on the NSE under the symbol SUDEEPPHRM and on the BSE under the scrip code 544619.
In Q2 FY27, Sudeep Pharma Limited reported revenue of ₹197 Cr and net profit of ₹52 Cr, with basic EPS of ₹4.59 (consolidated, parsed from the company's exchange filing).
Sudeep Pharma Limited reported revenue of ₹197 Cr in Q2 FY27, up 20.9% from ₹163 Cr in Q2 FY26 and up 24.3% from ₹158 Cr in Q1 FY27.
Promoters held 76.15% of Sudeep Pharma Limited's shares as of Sept 2026, unchanged from Nov 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.